51. The clinical relevance of oliguria in the critically ill patient : analysis of a large observational databaseJean Louis Vincent, Andrew Ferguson, Peter Pickkers, Stephan M. Jakob, Ulrich Jaschinski, Ghaleb A. Almekhlafi, Marc Leone, Majid Mokhtari, Luis E. Fontes, Philippe R. Bauer, Yasser Sakr, 2020, izvirni znanstveni članek Povzetek: Background: Urine output is widely used as one of the criteria for the diagnosis and staging of acute renal failure, but few studies have specifically assessed the role of oliguria as a marker of acute renal failure or outcomes in general intensive care unit (ICU) patients. Using a large multinational database, we therefore evaluated the occurrence of oliguria (defined as a urine output < 0.5 ml/kg/h) in acutely ill patients and its association with the need for renal replacement therapy (RRT) and outcome. Methods: International observational study. All adult (> 16 years) patients in the ICON audit who had a urine output measurement on the day of admission were included. To investigate the association between oliguria and mortality, we used a multilevel analysis. Results: Of the 8292 patients included, 2050 (24.7%) were oliguric during the first 24 h of admission. Patients with oliguria on admission who had at least one additional 24-h urine output recorded during their ICU stay (n = 1349) were divided into three groups: transient-oliguria resolved within 48 h after the admission day (n = 390 [28.9%]), prolonged-oliguria resolved > 48 h after the admission day (n = 141 [10.5%]), and permanent-oliguria persisting for the whole ICU stay or again present at the end of the ICU stay (n = 818 [60.6%]). ICU and hospital mortality rates were higher in patients with oliguria than in those without, except for patients with transient oliguria who had significantly lower mortality rates than non-oliguric patients. In multilevel analysis, the need for RRT was associated with a significantly higher risk of death (OR = 1.51 [95% CI 1.19%1.91], p = 0.001), but the presence of oliguria on admission was not (OR = 1.14 [95% CI 0.97%1.34], p = 0.103). Conclusions: Oliguria is common in ICU patients and may have a relatively benign nature if only transient. The duration of oliguria and need for RRT are associated with worse outcome. Ključne besede: critical care, critical illness, urine, oliguria, kidney, renal insufficiency, kidney diseases, acute kidney failure, mortality, urine output, renal replacement therapy Objavljeno v DiRROS: 18.11.2020; Ogledov: 1683; Prenosov: 1044 Celotno besedilo (727,74 KB) Gradivo ima več datotek! Več... |
52. Lung cancer biomarker testing : perspective from EuropeErik Thunnissen, Birgit Weynand, Dalma Udovicic-Gagula, Luka Brčić, Malgorzata Szolkowska, Paul Hofman, Silvana Smojver-Ježek, Sisko Anttila, Fiorella Calabrese, Izidor Kern, 2020, pregledni znanstveni članek Povzetek: A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future. Ključne besede: lung neoplasms -- diagnosis -- therapy -- Europe, lung cancer, predictive testing Objavljeno v DiRROS: 21.09.2020; Ogledov: 1705; Prenosov: 1081 Celotno besedilo (1,80 MB) Gradivo ima več datotek! Več... |
53. Naše izkušnje z zdravilom bevacizumab v primarnem zdravljenju epitelijskega raka jajčnikovErik Škof, Dushan Mangaroski, 2020, izvirni znanstveni članek Povzetek: Izhodišče: Zdravilo bevacizumab uporabljamo v sklopu primarnega sistemskega zdravljenja napredovalega epitelijskega raka jajčnikov v kombinaciji s paklitakselom in karboplatinom od leta 2013.
Namen: Prikazati učinkovitost in varnost zdravljenja z bevacizumabom v redni klinični praksi v sklopu primarnega zdravljenja raka jajčnikov.
Metode: V retrospektivno analizo smo vključili bolnice z epitelijskim rakom jajčnikov, ki so se zdravile z bevacizumabom na Onkološkem inštitutu Ljubljana v obdobju od 1. 1. 2013 do 31. 12. 2016. Cilja raziskave sta bila varnost in učinkovitost (preživetje brez ponovitve bolezni, celokupno preživetje) zdravljenja z bevacizumabom. Raziskavo je odobrila etična komisija na Onkološkem inštitutu Ljubljana.
Rezultati: V opazovanem obdobju je bilo z bevacizumabom zdravljenih 111 bolnic z napredovalim epitelijskim rakom jajčnikov. Najpogostejši neželeni učinki so bili: bolečine (52 %), krvavitev (45 %), arterijska hipertenzija (44 %). Resne neželene učinke (stopnja 3/4) je imelo 12 % bolnic: venska tromboza/ embolija (3 %), proteinurija (3 %), arterijska hipertenzija (2 %), krvavitev (2 %), bolečine (1 %), fistula (1 %). Mediani čas sledenja je bil 59 mesecev. Mediano preživetje brez ponovitve bolezni je bilo 18 mesecev, mediano celokupno preživetje pa 41 mesecev.
Zaključki: Zdravljenje z bevacizumabom v redni klinični praksi je varno in učinkovito ‒ v skladu z do zdaj znanimi rezultati prospektivnih raziskav GOG 218 in ICON 7.
Ključne besede: rak jajčnikov, epitelijski rak, bevacizumab, kemoterapija Objavljeno v DiRROS: 09.09.2020; Ogledov: 1985; Prenosov: 518 Celotno besedilo (173,87 KB) |
54. Rak trebušne slinavke : kaj morate vedeti o bolezni?Janja Ocvirk, Martina Reberšek, Zvezdana Hlebanja, Erik Škof, Irena Oblak, Vaneja Velenik, Franc Anderluh, 2008, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: dejavniki tveganja, simptomi, diagnostika, zdravljenje, bolečina Objavljeno v DiRROS: 10.08.2020; Ogledov: 1791; Prenosov: 705 Celotno besedilo (1,52 MB) |
55. Postopki za obravnavo bolnic z rakom materničnega vratuBarbara Šegedin, Sonja Bebar, Olga Cerar, Branko Cvjetičanin, Barbara Gazić, Brigita Gregorič, Urška Ivanuš, Borut Kobal, Manja Šešek, Leon Meglič, Maja Pakiž, Nina Kovačević, Špela Smrkolj, Erik Škof, Iztok Takač, Helena Barbara Zobec Logar, 2019, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: ONKOLOGIJA-STOJIŠČE, onkologija, ginekologija Objavljeno v DiRROS: 10.06.2020; Ogledov: 1873; Prenosov: 576 Celotno besedilo (717,48 KB) |
56. Rak želodca : kaj morate vedeti o bolezni?Franc Anderluh, Andrej Marušič, Irena Oblak, Janja Ocvirk, Martina Reberšek, Erik Škof, Vaneja Velenik, 2006, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: dejavniki tveganja, simptomi, diagnostika, zdravljenje Objavljeno v DiRROS: 10.06.2020; Ogledov: 1718; Prenosov: 462 Celotno besedilo (826,32 KB) |
57. Inter-individual variability in spring phenology of temperate deciduous trees depends on species, tree size and previous year autumn phenologyLorène Julia Marchand, Inge Dox, Jožica Gričar, Peter Prislan, Sebastien Leys, Jan Van den Bulcke, Patrick Fonti, Holger Lange, Erik Matthysen, Josep Peñuelas, Paolo Zuccarini, Matteo Campioli, 2020, izvirni znanstveni članek Povzetek: We explored the inter-individual variability in bud-burst and its potential drivers, in homogeneous mature stands of temperate deciduous trees. Phenological observations of leaves and wood formation were performed weekly from summer 2017 to summer 2018 for pedunculate oak, European beech and silver birch in Belgium. The variability of bud-burst was correlated to previous' year autumn phenology (i.e. the onset of leaf senescence and the cessation of wood formation) and tree size but with important differences among species. In fact, variability of bud-burst was primarily related to onset of leaf senescence, cessation of wood formation and tree height for oak, beech and birch, respectively. The inter-individual variability of onset of leaf senescence was not related to the tree characteristics considered and was much larger than the inter-individual variability in bud-burst. Multispecies multivariate models could explain up to 66% of the bud-burst variability. These findings represent an important advance in our fundamental understanding and modelling of phenology and tree functioning of deciduous tree species. Ključne besede: leaf unfolding, wood formation, coloration, Pedunculate oak, European beech, Silver birch Objavljeno v DiRROS: 10.06.2020; Ogledov: 1946; Prenosov: 1136 Povezava na celotno besedilo Gradivo ima več datotek! Več... |
58. Priporočila za obravnavo bolnic z rakom materničnega vratuBarbara Šegedin, Darja Arko, Sonja Bebar, Olga Cerar, Branko Cvjetičanin, Barbara Gazić, Brigita Gregorič, Urška Ivanuš, Borut Kobal, Manja Šešek, Leon Meglič, Maja Pakiž, Nina Kovačević, Špela Smrkolj, Erik Škof, Iztok Takač, Helena Barbara Zobec Logar, 2019, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: diagnostika, kirurško zdravljenje, radikalno zdravljenje, kemoterapija, sledenje pacientov, nosečnice, zdravstvena obravnava, recidiv, paliativna oskrba, epidemiologija, histopatologija, smernice Objavljeno v DiRROS: 10.06.2020; Ogledov: 1953; Prenosov: 653 Celotno besedilo (984,88 KB) |
59. Smernice za obravnavo bolnic z rakom jajčnikov, jajcevodov in s primarnim peritonealnim seroznim rakomMatija Barbič, Sonja Bebar, Olga Cerar, Branko Cvjetičanin, Janka Čarman, Astrid Djurišić, Snježana Frković-Grazio, Barbara Gazić, Andreja Gornjec, Katja Jakopič, Borut Kobal, Mateja Krajc, Sebastjan Merlo, Maja Marolt-Mušič, Maja Pakiž, Špela Smrkolj, Manja Šešek, Erik Škof, Iztok Takač, Aleš Vakselj, Vesna Zadnik, Helena Barbara Zobec Logar, 2015, strokovna monografija Ključne besede: zdravstvena obravnava, smernice, rak jajčnikov, ginekologija, neoplazme, ginekološki raki Objavljeno v DiRROS: 09.06.2020; Ogledov: 1824; Prenosov: 572 Celotno besedilo (955,32 KB) |
60. Olaparib za zdravljenje raka jajčnikovErik Škof, Ksenija Strojnik, 2016, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: rak jajčnikov, zaviralci PARP, olaparib, gen dovzetnosti za pojav raka dojk, BRCA Objavljeno v DiRROS: 04.06.2020; Ogledov: 1900; Prenosov: 474 Celotno besedilo (462,66 KB) |